πŸ‡ΊπŸ‡Έ FDA
Patent

US 10913709

STAT3 inhibitor formulation

granted A61KA61K31/197A61K9/0053

Quick answer

US patent 10913709 (STAT3 inhibitor formulation) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Feb 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Feb 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K31/197, A61K9/0053, A61K9/08, A61P